Skip to main content

Advertisement

SpringerLink
Log in

CD147 and glioma: a meta-analysis

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Gliomas are the most common primary brain tumors. This meta-analysis aimed to systematically evaluate the relationship between CD147 expression in tissues and the clinicopathological features of patients with glioma. We searched PubMed (1966–2016), EMBASE (1980–2016), Cochrane Library (1996–2016), Web of Science (1945–2016), China National Knowledge Infrastructure (1982–2016), and Wan Fang databases (1988–2016). Quality assessment of the literature was performed using the Newcastle–Ottawa Scale, with Revman 5.3 and Stata 14.0 for analysis. In total, 1806 glioma patients from 19 studies were included, and patients with CD147 overexpression had poorer overall survival [hazard ratio (HR) = 2.211, P < 0.0001], a higher risk of recurrence (HR = 2.20, P = 0.0025), and a lower 5-year survival rate [odds ratio (OR) 0.12; 95% CI 0.08–0.19; P < 0.00001]. We observed significant differences in CD147 expression when comparing glioma tissues versus non-cancerous brain tissues (OR 20.42; 95% CI 13.94–29.91; P < 0.00001), tumor grades III–IV versus grades I–II (OR 5.88, 95% CI 4.15–8.34; P < 0.00001), and large versus small tumors (OR 1.58, 95% CI 1.04–2.40; P = 0.03). We also observed a significant correlation with matrix metalloproteinase (MMP) 2 (OR 39.11, 95% CI 11.47–133.34; P < 0.00001) and MMP9 (OR 13.35, 95% CI 4.67–38.18; P < 0.00001). CD147 expression did not differ based on patient’s age (young vs. old, P = 0.89) or gender (female vs. male, P = 0.57). CD147 expression may be a potential prognostic biomarker for poorer overall and relapse-free survival, and may affect the 5-year survival rate in glioma patients. CD147 expression is also closely correlated with poor clinical characteristics in glioma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Burger PC (1995) Revising the World Health Organization (WHO) Blue Book—‘histological typing of tumours of the central nervous system’. J Neurooncol 24(1):3–7

    Article  CAS  PubMed  Google Scholar 

  2. Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820

    Article  PubMed  Google Scholar 

  3. Stupp R, Tonn JC, Brada M et al (2010) High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v190–v193

    Article  PubMed  Google Scholar 

  4. Han M, Guo L, Zhang Y et al (2016) Clinicopathological and prognostic significance of CD133 in glioma patients: a meta-analysis. Mol Neurobiol 53(1):720–727

    Article  CAS  PubMed  Google Scholar 

  5. Zhang W, Chen H, Lv S et al (2016) High CD133 expression is associated with worse prognosis in patients with glioblastoma. Mol Neurobiol 53(4):2354–2360

    Article  CAS  PubMed  Google Scholar 

  6. Wu B, Sun C, Feng F et al (2015) Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis. J Exp Clin Cancer Res 34:44

    Article  PubMed  PubMed Central  Google Scholar 

  7. Yi GZ, Feng WY, Zhou Q et al (2016) The impact of MMP-2 and its specific inhibitor TIMP-2 expression on the WHO grade and prognosis of gliomas in Chinese population: a meta-analysis. Mol Neurobiol 54:22–30

    Article  PubMed  PubMed Central  Google Scholar 

  8. Chen W, He D, Li Z et al (2015) Overexpression of vascular endothelial growth factor indicates poor outcomes of glioma: a systematic review and meta-analysis. Int J Clin Exp Med 8(6):8709–8719

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Bao Z, Zhang C, Yan W et al (2013) BMP4, a strong better prognosis predictor, has a subtype preference and cell development association in gliomas. J Transl Med 11:100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gonzalez-Gomez P, Anselmo NP, Mira H (2014) BMPs as therapeutic targets and biomarkers in astrocytic glioma. Biomed Res Int 2014:549742

    Article  PubMed  PubMed Central  Google Scholar 

  11. Wang Y, Jiang T (2013) Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett 331(2):139–146

    Article  CAS  PubMed  Google Scholar 

  12. Gabison EE, Mourah S, Steinfels E et al (2005) Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metalloproteinase induction. Am J Pathol 166(1):209–219

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yu XL, Hu T, Du JM et al (2008) Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion. J Biol Chem 283(26):18056–18065

    Article  CAS  PubMed  Google Scholar 

  14. Sameshima T, Nabeshima K, Toole BP et al (2000) Expression of emmprin (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas. Int J Cancer 88(1):21–27

    Article  CAS  PubMed  Google Scholar 

  15. Ishibashi Y, Matsumoto T, Niwa M et al (2004) CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 101(9):1994–2000

    Article  CAS  PubMed  Google Scholar 

  16. Peng F, Li H, Ning Z et al (2016) CD147 and prostate cancer: a systematic review and meta-analysis. PLoS ONE 11(9):e163678

    Google Scholar 

  17. Renno T, Wilson A, Dunkel C et al (2002) A role for CD147 in thymic development. J Immunol 168(10):4946–4950

    Article  CAS  PubMed  Google Scholar 

  18. Dalberg K, Eriksson E, Enberg U et al (2000) Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J Surg 24(3):334–340

    Article  CAS  PubMed  Google Scholar 

  19. Yang M, Yuan Y, Zhang H et al (2013) Prognostic significance of CD147 in patients with glioblastoma. J Neurooncol 115(1):19–26

    Article  CAS  PubMed  Google Scholar 

  20. Gu J, Zhang C, Chen R et al (2009) Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. Eur J Pediatr 168(6):705–710

    Article  CAS  PubMed  Google Scholar 

  21. Jiang T, Zhao B, Li X et al (2016) ARPP-19 promotes proliferation and metastasis of human glioma. NeuroReport 27(13):960–966

    Article  CAS  PubMed  Google Scholar 

  22. Wang Y, Sun S, Liu Q (2015) Expression and significance of Bmi-1, CD147 and PCNA in glioma tissue after operation. Chin J Gerontol (8):2205–2206

  23. Duval SART (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463

    Article  CAS  PubMed  Google Scholar 

  24. Tsai WC, Chen Y, Huang LC et al (2013) EMMPRIN expression positively correlates with WHO grades of astrocytomas and meningiomas. J Neurooncol 114(3):281–290

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Zou Z, Yang H, Xia J et al (2015) Expression and correlation of EMMPRIN, MMP-2 and MMP-9 in astrocytoma. Guide China Med 13(13):191

  26. Ye H (2013) Expression of CD147 in human brain gliomas and its correlations with the tumor proliferation and invasion. Taishan Med Univ

  27. Wang X (2006) The expression of MCT1 and CD147 in human gliomas and the influence of CD147 genetic engineering antibody on glioma cells glycolysis metabolism in vitro. Sichuan Univ

  28. Shi Q, Zhi X (2006) Expression of CD147 and its relationship with the expression of MMP-2 in glioma. Acta Acad Med Jiangxi 46(1):19–22

  29. Liu P, Ren Q, Li Z et al (2011) Expression and significance of CD147 and MMP-2 in human gliomas. J Binzhou Med Univ 34(4):264–266

  30. Liu P (2006) The expression and significance of CD147, MMP-2, and MMP-9 in human glioma. Chongqing Med Univ

  31. Liang Q (2007) Experimental study of Basigin/CD147 in glioblastoma progression and its antisense RNA in inhibiting tumor cell invasion and angiogenesis. Fourth Mil Med Univ

  32. Gu J (2014) Expression of CD147 and its clinical significance in human glioma tissues. Clinical Medicine (Department of Neurosurgery), Shantou University

  33. Chen Q, Zou Z, Zhang H et al (2006) Expressions and significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase-9 in human brain astrocytoma. Chin J Clin Neurosurg 11(3):143–145

  34. Tian L, Zhang Y, Chen Y et al (2013) EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma. PLoS ONE 8(3):e58069

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Li H, Chen J, He M et al (2007) Expression of CD147 and MMP-2 in human gliomas and its correlations with prognosis. Sichuan Da Xue Xue Bao Yi Xue Ban 38(3):396–399

    CAS  PubMed  Google Scholar 

  36. Chu T, Chen X, Yu J et al (2011) Extracellular matrix metalloproteinase inducer is a negative prognostic factor of pediatric medulloblastoma. Pathol Oncol Res 17(3):705–711

    Article  CAS  PubMed  Google Scholar 

  37. Ju H, Shen S, Geng H et al (2011) Expressions and correlation of CD147, MMP-9 and TIMP-1 in gliomas of different grade. Clin Med China 27(5):461–464

    Google Scholar 

  38. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605

    Article  PubMed  Google Scholar 

  39. Wang X, You C, Sun X (2010) Expressions of MCT1 and CD147 in human gliomas and their correlations with prognosis. Acta Acad Med Mil Tertiae 32(9):985–988

  40. Liang Q, Zhang H, Jing X et al (2008) Expression of CD147 in human glioma and its clinical significance. Chin J Neurooncol 6(4):228–231

  41. Marieb EA et al (2004) Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res 64(4):1229–1232

    Article  CAS  PubMed  Google Scholar 

  42. Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327–336

    Article  CAS  PubMed  Google Scholar 

  43. Yu YH, Morales J, Feng L et al (2015) CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: a tissue microarray study. Oral Surg Oral Med Oral Pathol Oral Radiol 119(5):553–565

    Article  PubMed  PubMed Central  Google Scholar 

  44. Gou X, Chen H, Jin F et al (2014) Expressions of CD147, MMP-2 and MMP-9 in laryngeal carcinoma and its correlation with poor prognosis. Pathol Oncol Res 20(2):475–481

    Article  CAS  PubMed  Google Scholar 

  45. Liu Y, Xin T, Jiang QY et al (2013) CD147, MMP9 expression and clinical significance of basal-like breast cancer. Med Oncol 30(1):366

    Article  PubMed  Google Scholar 

  46. Chen H, Wang L, Beretov J et al (2010) Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clin Exp Metastasis 27(8):557–569

    Article  CAS  PubMed  Google Scholar 

  47. Huang XQ, Chen X, Xie XX et al (2014) Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma. Int J Clin Exp Pathol 7(4):1651–1666

    PubMed  PubMed Central  Google Scholar 

  48. Kong X, Wang Y, Dai C et al (2016) Is CD147 a new biomarker reflecting histological malignancy of gliomas? Mol Neurobiol 20:1–9

    Google Scholar 

  49. Han S, Dong T, Yu C et al (2014) Expressions of MCT1 and CD147 in human gliomas and their correlations with prognosis. Chin J Pract Nerv Dis 17(1):1–3

  50. Guo Y, Suo X, Wang W et al (2009) Expressions and their significance of extracellular matrix metalloproteinase inducer mRNA and laminin receptor mRNA in human gliomas. Chin J Minim Invasive Neurosurg 14(10):462–464

  51. Xin X, Zeng X, Gu H et al (2016) CD147/EMMPRIN overexpression and prognosis in cancer: a systematic review and meta-analysis. Sci Rep 6:32804

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Reproductive Department, Xiangya Hospital, Central South University, Changsha, China

    Hui Li

  2. Xiangya Hospital, Central South University, Changsha, China

    Zhouhuan Xi

  3. Xiangya School of Medicine, Central South University, Changsha, China

    Xuejiao Dai, Wenyue Wu, Yanwen Li, Yanting Liu & Hanwen Zhang

Authors
  1. Hui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhouhuan Xi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xuejiao Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenyue Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yanwen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yanting Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hanwen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hui Li.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Research involving Human Participants and/or Animals

This chapter does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Hui Li and Zhouhuan Xi have contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 16 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, H., Xi, Z., Dai, X. et al. CD147 and glioma: a meta-analysis. J Neurooncol 134, 145–156 (2017). https://doi.org/10.1007/s11060-017-2499-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-017-2499-4

Keywords

Search

Navigation